Antimetabolites -- DNA-intercalators — the anthracyclines -- Topoisomerase inhibitors -- Tubulin interacting agents -- Vaccination therapies in solid tumors -- Oral anticancer agents -- Anti-angiogenesis agents -- Signal transduction inhibitors -- Endocrine therapy of breast cancer.

During recent years the field of effective anticancer agents has substantially increased. The use of chemotherapy has been accepted as a standard therapy for an expanding number of tumour types and stages, while many new agents are being investigated when standard therapy is lacking or failing. Apart from new targets for anticancer agents, attention is also focused on improving efficacy and tolerability of existing compounds. This topical volume provides an up-to-date overview of clinically relevant data on anticancer agents, and is not only intended for those working as a medical doctor with cancer patients, but also for medical researchers and students. The different classes of anticancer drugs are described by international authorities on the various topics.